STOCK TITAN

ProQR Therapeutics N.V. (PRQR) Stock Price, News & Analysis

PRQR NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
69 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+19.6% close of June 29, 2026
1-year change
-49.5% closing prices, November 20, 2025 to November 20, 2026
1-month change
-24.6% closing prices, October 20, 2026 to November 20, 2026

Company Description

ProQR Therapeutics N.V. (Nasdaq: PRQR) is a clinical-stage biopharmaceutical company focused on RNA-based medicines. According to its public disclosures, ProQR is dedicated to changing lives through the creation of transformative RNA therapies and is pioneering a next-generation RNA base editing technology called Axiomer™. The company states that Axiomer uses a cell’s own editing machinery, known as ADAR (Adenosine Deaminase Acting on RNA), to make specific single nucleotide edits in RNA that may reverse a mutation, modulate protein expression, or alter a protein so that it has a new function that helps prevent or treat disease.

ProQR describes itself as a company building an RNA editing pipeline for both rare and more prevalent diseases with unmet medical need. Its work is positioned in the biopharmaceutical and RNA therapeutics space, with a focus on editing oligonucleotides that can change single nucleotides in RNA in a targeted way. Based on its public statements, ProQR is growing its pipeline using proprietary RNA repair platform technologies, with patients and their families as the central focus of its development strategy.

Axiomer™ RNA Editing Technology

In company materials, ProQR explains that its Axiomer technology is a next-generation RNA base editing platform. Axiomer "Editing Oligonucleotides" (EONs) are designed to mediate single nucleotide changes to RNA in a highly specific and targeted way. These EONs recruit and direct endogenously expressed ADAR enzymes to change an adenosine (A) to an inosine (I) in RNA. Because an inosine is translated as a guanosine (G), this approach can correct an RNA with a disease-causing mutation back to a normal (wild-type) RNA, modulate protein expression, or alter a protein to provide a potentially beneficial function.

ProQR highlights three broad applications of its Axiomer platform in its disclosures: using RNA editing to correct disease-causing mutations, to modulate protein function, and to protect against disease by mimicking beneficial variants. The platform is described as having potential relevance for diverse disease areas, including liver and central nervous system (CNS) indications, as reflected in the company’s pipeline programs.

Pipeline and Key Programs

Based on recent press releases and SEC filings, ProQR’s pipeline includes several named development programs built on the Axiomer RNA editing platform:

  • AX-0810: Described as ProQR’s lead investigational RNA editing oligonucleotide (EON), AX-0810 targets NTCP, a liver cell protein that transports bile acids into cells. The company states that AX-0810 is being developed for cholestatic diseases such as primary sclerosing cholangitis and biliary atresia. AX-0810 is characterized as a first-in-class investigational RNA editing oligonucleotide that harnesses endogenous ADAR enzymes to selectively modulate NTCP function, with the aim of reducing toxic bile acid accumulation in the liver and improving outcomes in cholestatic diseases.
  • AX-2402: ProQR identifies AX-2402 as a development program targeting MECP2 for Rett syndrome (R270X). The company reports that it has selected a development candidate for AX-2402 based on a preclinical profile that supports advancement to development activities. Non-clinical proof-of-concept data in a mouse model of Rett syndrome with the MECP2 R270X mutation showed statistically significant and clinically relevant functional improvements, including improvements in cumulative Bird score and hindlimb clasping score. ProQR also notes that AX-2402 is supported by funding from the Rett Syndrome Research Trust (RSRT).
  • AX-2911: This program targets the PNPLA3 I148M mutation, which ProQR describes as a key genetic driver for metabolic liver disease, including metabolic-associated steatohepatitis (MASH). The company states that it has selected a development candidate for AX-2911 based on preclinical proof-of-concept data demonstrating on-target RNA editing, favorable potency, and supportive in vitro and in vivo functional data. In a humanized PNPLA3-148M mouse model fed a Western diet, AX-2911 was reported to show a reduction in hepatic fat content in head-to-head comparison with a clinical-stage PNPLA3-directed antisense therapy.
  • AX-1412: ProQR describes AX-1412 as a program that demonstrates the protective application of Axiomer, mimicking a naturally occurring B4GALT1 variant associated with reduced cardiovascular risk. Company disclosures indicate that AX-1412 is being optimized for GalNAc delivery and is part of its cardiovascular disease-focused work.

In addition to these named programs, ProQR refers to earlier-stage Axiomer pipeline efforts across liver and CNS applications, and notes that it is expanding preclinical in vivo and in vitro data to support potential future development.

Clinical Development and Studies

ProQR reports that AX-0810 is the first program from its Axiomer RNA editing pipeline to enter clinical development. The company describes an ongoing Phase 1 first-in-human study of AX-0810 in healthy volunteers in the Netherlands. According to company communications, the study is a single-center, randomized, double-blind, placebo-controlled, multiple dose escalation trial. Up to 33 participants are expected to be enrolled, with AX-0810 given as subcutaneous injections over four weeks followed by a safety follow-up period. The objectives include evaluation of safety, tolerability, pharmacokinetics (PK), and confirmation of target engagement using biomarkers.

Initial data from the first cohort of healthy volunteers at a specified dose level have been reported by ProQR to show no serious adverse events or clinically meaningful laboratory abnormalities and pharmacokinetics consistent with non-clinical data. The company indicates that these observations support continued dosing according to the study design and that target engagement data from healthy volunteer cohorts are expected within a defined timeframe, followed by inclusion of a patient cohort in the same Phase 1 trial.

Strategic Collaboration and Capital

ProQR has publicly disclosed a strategic collaboration with Eli Lilly and Company (Lilly). The company reports that this collaboration is focused on its Axiomer RNA editing platform and that it has achieved milestone payments under the agreement. ProQR characterizes the collaboration as providing non-dilutive capital and as external validation of the Axiomer platform. In its financial updates, ProQR notes milestone income from the Lilly collaboration and references the potential for additional milestones and an option for Lilly to expand the number of targets under the collaboration.

In quarterly financial results, ProQR reports holding cash and cash equivalents and describes a cash runway into a specified period, supported in part by collaboration milestones. These disclosures indicate that the company is funding research and development activities, including clinical trials and platform development, through a combination of its cash resources and collaboration income.

Research, Conferences, and Scientific Presence

ProQR regularly highlights its participation in scientific and investor conferences. Company announcements reference presentations at meetings such as the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, the RNA Editing Summit, the Oligonucleotide Therapeutics Society (OTS) Annual Meeting, and TIDES USA, among others. These presentations cover topics including ADAR-mediated RNA editing of NTCP for cholestatic diseases, correction of PNPLA3 I148M functionality to address hepatic steatosis, and RNA editing of MECP2 for Rett syndrome.

The company also notes participation in healthcare and genetic medicines investor conferences and virtual analyst and investor events, where it discusses its AX-0810 trial design, biomarker strategy, and broader Axiomer pipeline. Through these activities, ProQR presents preclinical and early clinical data, as well as updates on its platform and pipeline programs.

Business Focus and Segment

In the industry classification provided, ProQR is associated with pharmaceutical preparation manufacturing within the broader manufacturing sector. In its own descriptions, the company identifies as a biopharmaceutical organization with a single reportable segment focused on the discovery and development of RNA-based therapeutics. Its work centers on RNA editing oligonucleotides and related platform technologies rather than on multiple distinct operating segments.

ProQR’s disclosures emphasize that its pipeline and platform are intended to address diseases with high unmet need, including rare genetic disorders and metabolic and cardiovascular conditions with a genetic component. The company’s approach is to use RNA editing to modulate or correct disease-relevant targets at the RNA level, guided by human genetics and preclinical data.

Stock and Regulatory Reporting

ProQR Therapeutics N.V. trades on Nasdaq under the ticker symbol PRQR. As a foreign private issuer, it files annual reports on Form 20-F and periodic current reports on Form 6-K with the U.S. Securities and Exchange Commission. Recent 6-K filings referenced by the company include press releases and unaudited financial statements for quarterly periods, as well as materials related to analyst and investor events and key clinical and regulatory milestones such as the submission and authorization of a Clinical Trial Application for AX-0810.

Stock Performance

$1.04
-0.95%
-0.01
Last updated: at
-49.5%
Performance 1 year
$147.0M

ProQR Therapeutics N.V. (PRQR) closed at $1.04 on November 20, 2026. Over the past 12 months, the price has lost 49.5%.

See what a $1,000 investment in PRQR would be worth today

Average down calculator for PRQR

PRQR Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

ProQR Therapeutics N.V. has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, management, AI, clinical trial, conferences. View all PRQR news →

Financial Highlights

ProQR Therapeutics N.V. generated $18.7M in revenue in FY2025, operating income reached -$51.0M, and net income was -$49.5M. Diluted earnings per share stood at -$0.47. The company generated -$62.0M in operating cash flow. The current ratio was 3.09, measuring current assets divided by current liabilities.

$18.7M
Revenue (FY2025)
-$49.5M
Net Income (FY2025)
-$62.0M
Operating Cash Flow

Upcoming Events

DEC
2026
December 2026 Clinical

AX-0810 Phase 1 dataset

Topline full AX-0810 Phase 1 dataset expected in December 2026; readout likely to affect program valuation and next steps.
DEC
09
December 9, 2026 Clinical

Nature conference presentation

Nature conference talk presenting AX-0810 cohort 3 12-week follow-up data and new AX-0811 preclinical proof-of-concept.
YEAR
2026
2026 Clinical

AX-0811 initial data

Initial healthy-volunteer data for AX-0811 anticipated by year-end 2026; follows EMA CTA submission; key clinical validation readout.
YEAR
2027
2027 Regulatory

AX-0422 CTA filing

CTA filings for AX-0422 planned early 2027; company to provide timeline and regulatory updates for first-in-human steps.
H1
2027
H1 2027 Clinical

IIT biliary atresia data

Investigator-initiated trial data in pediatric biliary atresia expected in H1 2027; ProQR to report timing and study results.
JAN
2027
January 2027 Clinical

AX-0811 target engagement

Initial AX-0811 target engagement data expected in early January 2027; first human pharmacology signals for the program.
H1
2027
H1 2027 Clinical

Biliary atresia trial start

Pediatric biliary atresia trial initiation targeted in H1 2027, with initial data also expected during this first-half period.
H1
2027
H1 2027 Clinical

AX-0422 initial data

Initial AX-0422 patient data targeted in H1 2027; early clinical readouts may inform development trajectory.
H1
2027
H1 2027 Clinical

AX-2911 clinical entry

AX-2911 planned to enter the clinic in H1 2027, marking a new program advancement into human testing.
JAN
2027
January 2027 Clinical

AX-0811 target data

Target engagement data from the first two AX-0811 cohorts anticipated in early January 2027; timing focused on cohort readouts.
JAN
2027
January 2027 Clinical

Initial target engagement

AX-0811 Phase 1: generation of initial target engagement data for the first two cohorts in healthy volunteers expected early January 2027.
YEAR
2027
2027 Clinical

AX-0811 initial data

Initial AX-0811 Phase 1 data in healthy volunteers expected in early 2027; company anticipates reporting initial results.
YEAR
2027
2027 Clinical

IIT pediatric biliary atresia

Investigator-initiated trial in pediatric biliary atresia planned as a 2027 milestone; timing reported broadly within 2027 timeframe.
YEAR
2027
2027 Clinical

AX-0422 first-in-patient

First-in-patient clinical data for AX-0422 expected during 2027 per company roadmap; constitutes a key clinical development milestone.
YEAR
2027
2027 Clinical

AX-2911 first-in-patient

First-in-patient clinical data for AX-2911 anticipated in 2027 under ProQR's outlined milestones; timing given broadly for 2027.
YEAR
2027
2027 Clinical

Phase 2 program start

Potential registration-enabling Phase 2 program expected to start in mid-2027, subject to regulatory interactions.

ProQR Therapeutics N.V. has 16 upcoming scheduled events. The next event, "AX-0810 Phase 1 dataset", is expected in December 2026. Investors can track these dates to stay informed about potential catalysts that may affect the PRQR stock price.

Short Interest History

Last 12 Months

Short interest in ProQR Therapeutics N.V. (PRQR) currently stands at 2.9 million shares, down 0.7% from the previous reporting period, representing 2.7% of the shares outstanding. Since November 2025, short interest has increased by 171.8%.

Days to Cover History

Last 12 Months

Days to cover for ProQR Therapeutics N.V. (PRQR) currently stands at 2.9 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 6.9 days.

PRQR Company Profile & Sector Positioning

ProQR Therapeutics N.V. (PRQR) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PRQR often look at related companies in the same sector, including Sutro Biopharma, Inc. (STRO), Korro Bio, Inc. (KRRO), InflaRx N.V. (IFRX), Zentalis Pharmaceuticals, Inc. (ZNTL), and Palisade Bio, Inc. (PALI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PRQR's relative position within its industry.

Frequently Asked Questions

The current stock price of ProQR Therapeutics N.V. (PRQR) is $1.04 as of November 20, 2026.

The market cap of ProQR Therapeutics N.V. (PRQR) is approximately $147.0M. Learn more about what market capitalization means .

The FY2025 revenue of ProQR Therapeutics N.V. (PRQR) is $18.7M, from its most recent completed fiscal year.

The FY2025 net income of ProQR Therapeutics N.V. (PRQR) is -$49.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of ProQR Therapeutics N.V. (PRQR) is -$0.47 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of ProQR Therapeutics N.V. (PRQR) is -$62.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of ProQR Therapeutics N.V. (PRQR), current assets divided by current liabilities, was 3.09 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of ProQR Therapeutics N.V. (PRQR) is -$51.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

ProQR Therapeutics N.V. is a biopharmaceutical company that describes itself as dedicated to changing lives through the creation of transformative RNA therapies. It is pioneering the Axiomer RNA editing technology platform to develop RNA-based medicines for diseases with unmet medical need.

Axiomer is ProQR’s next-generation RNA base editing platform. According to the company, Axiomer Editing Oligonucleotides recruit endogenous ADAR enzymes to change specific adenosines in RNA to inosines, which are read as guanosines. This can correct disease-causing mutations, modulate protein expression, or alter protein function for therapeutic purposes.

ProQR’s disclosures indicate a focus on liver and central nervous system diseases and other conditions with a genetic component. Its named programs target cholestatic liver diseases via NTCP (AX-0810), Rett syndrome via MECP2 R270X (AX-2402), metabolic-associated steatohepatitis and related metabolic liver disease via PNPLA3 I148M (AX-2911), and cardiovascular disease via a B4GALT1-focused program (AX-1412).

AX-0810 is ProQR’s lead investigational RNA editing oligonucleotide targeting NTCP, a liver cell protein involved in bile acid transport. The company reports that AX-0810 is being developed for cholestatic diseases and is in a Phase 1 first-in-human study in healthy volunteers to evaluate safety, tolerability, pharmacokinetics, and target engagement.

ProQR’s AX-2402 program targets the MECP2 R270X mutation associated with Rett syndrome. The company has selected a development candidate based on preclinical data and has reported non-clinical proof-of-concept in a mouse model of Rett syndrome, including functional improvements. AX-2402 is supported by funding from the Rett Syndrome Research Trust.

AX-2911 is a development program that targets the PNPLA3 I148M mutation, which ProQR identifies as a key genetic driver of metabolic liver disease, including MASH. Preclinical data disclosed by the company show on-target RNA editing, potency, and functional effects on hepatic fat content in a humanized mouse model.

AX-1412 is described by ProQR as a program that demonstrates the protective application of its Axiomer platform. It aims to mimic a naturally occurring B4GALT1 variant associated with reduced cardiovascular risk. The company has indicated that it is working on optimization for GalNAc delivery for this program.

Yes. ProQR has announced a strategic collaboration with Eli Lilly and Company focused on its Axiomer RNA editing platform. The company reports achieving milestone payments under this collaboration and notes that it provides non-dilutive capital and external validation of the platform.

ProQR Therapeutics N.V. is listed on Nasdaq under the ticker symbol PRQR. As a foreign private issuer, it files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission.

In its quarterly Form 6-K filings and press releases, ProQR provides unaudited financial statements, including revenue, research and development costs, general and administrative costs, and net loss. The company reports its cash and cash equivalents and has stated that its cash position, together with collaboration milestones, provides a cash runway into a specified future period.